# Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). I. Clinical aspects

DOI: PM/6074578
Seminars in Hematology, 1967, 4, 233-40.

| # | Paper | IF | Citations |
|---|---|---|---|
| 246 | Familial aplastic anaemia without congenital malformations. **1969**, 58, 151-6 | | 19 |
| 245 | Triphalangeal thumbs and congenital erythroid hypoplasia: report of a case with unusual features. **1972**, 81, 987-9 | | 28 |
| 244 | Clinical Manifestations of Chromosome Disorders. **1974**, 197-270 | | 1 |
| 243 | Induction by alkylating agents of sister chromatid exchanges and chromatid breaks in Fanconi anemia. **1975**, 72, 4066-70 | | 213 |
| 242 | Multiple neoplasms in two siblings with a variant form of Fanconi anemia. **1975**, 36, 1029-33 | | 60 |
| 241 | Letter: Fanconi anemia: simultaneous onset of symptoms in two siblings. **1976**, 88, 152 | | 3 |
| 240 | Formal genetics of Fanconi anemia. *Human Genetics*, **1976**, 32, 257-88 | 6.3 | 168 |
| 239 | Cows milk allergy in the syndrome of thrombocytopenia with absent radius. **1976**, 51, 337-43 | | 49 |
| 238 | A female patient with "Aase syndrome". **1977**, 91, 753-5 | | 13 |
| 237 | SV40 T-antigen expression in skin fibroblasts from clinically normal individuals and from ten cases of Fanconi anemia. **1977**, 2, 33-40 | | 18 |
| 236 | Reduced frequencies of mitomycin-C induced sister chromatid exchanges in AKR mice. *Human Genetics*, **1978**, 41, 45-51 | 6.3 | 22 |
| 235 | Constitutional aplastic anaemia: defective haematopoietic stem cell growth in vitro. **1978**, 40, 277-87 | | 23 |
| 234 | Cimetidine and phytobezoars. **1978**, 2, 1263 | | 3 |
| 233 | Terminal deoxynucleotidyl transferase in Fanconi anaemia. **1978**, 2, 1263 | | 4 |
| 232 | A case of pure red cell aplasia with a high incidence of spontaneous chromosome breakage: a possible X-ray sensitive syndrome. *Human Genetics*, **1980**, 55, 337-40 | 6.3 | 12 |
| 231 | Lower limb anomalies in the thrombocytopenia absent-radius (TAR) syndrome. **1980**, 7, 523-8 | | 14 |
| 230 | Bone marrow transplantation in Fanconi anaemia. **1980**, 45, 557-64 | | 116 |

| | | | |
|---|---|---|---|
| 229 | Reduced uptake and incorporation of 3H-thymidine in Fanconi anemia fibroblasts. *Human Genetics*, **1981**, 57, 296-9 | 6.3 | 9 |
| 228 | Acute myeloid leukemia as the first hematologic manifestation of Fanconi anemia. **1982**, 12, 289-300 | | 35 |
| 227 | Multiple squamous-cell carcinomas in Fanconi anemia. **1982**, 50, 811-4 | | 43 |
| 226 | Analysis of heterogeneity in Fanconi anemia patients of different ethnic origin. *Human Genetics*, **1982**, 62, 321-3 | 6.3 | 11 |
| 225 | Cytogenetic toxicity of antitumor platinum compounds in Fanconi anemia. *Human Genetics*, **1982**, 61, 228-30 | 6.3 | 32 |
| 224 | Management of aplastic anaemia. **1983**, 53, 185-8 | | 10 |
| 223 | Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. **1983**, 54, 431-40 | | 153 |
| 222 | Effect of oxygen tension on chromosomal aberrations in Fanconi anaemia. *Human Genetics*, **1983**, 65, 99-101 | 6.3 | 51 |
| 221 | Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. *Human Genetics*, **1983**, 64, 384-7 | 6.3 | 43 |
| 220 | The association of Fanconi anemia and squamous cell carcinoma. **1983**, 52, 926-8 | | 39 |
| 219 | Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: relevance to bone marrow transplantation. **1983**, 9, 25-36 | | 34 |
| 218 | Clostridium liver abscess and massive hemolysis. Unique demise in Fanconi aplastic anemia. **1984**, 23, 126-7 | | 12 |
| 217 | Fanconi anemia. A family study with 20-year follow-up including associated breast pathology. **1984**, 54, 1850-3 | | 11 |
| 216 | Mitomycin C induced chromosome damage in fetal blood cultures and prenatal diagnosis of Fanconi anaemia. **1984**, 4, 217-21 | | 17 |
| 215 | Fanconi anaemia cells are not uniformly deficient in unhooking of DNA interstrand crosslinks, induced by mitomycin C or 8-methoxypsoralen plus UVA. *Human Genetics*, **1984**, 68, 228-34 | 6.3 | 58 |
| 214 | Familial thrombocytopenia associated with platelet autoantibodies and chromosome breakage. *Human Genetics*, **1984**, 65, 252-6 | 6.3 | 10 |
| 213 | Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts. **1984**, 132, 181-7 | | 17 |
| 212 | DNA semi-conservative synthesis in normal and Fanconi anemia fibroblasts following treatment with 8-methoxypsoralen and near ultraviolet light or with X-rays. *Human Genetics*, **1985**, 70, 236-42 | 6.3 | 48 |

| | | | |
|---|---|---|---|
| 211 | Severe aplastic anaemia. **1985**, 60, 295-6 | | 1 |
| 210 | Upper limb malformations associated with congenital heart disease. **1985**, 55, 1576-83 | | 19 |
| 209 | Treatment of acquired amegakaryocytic thrombocytopenic purpura with cyclophosphamide. **1986**, 81, 139-42 | | 13 |
| 208 | Abnormal response to DNA crosslinking agents of Fanconi anemia fibroblasts can be corrected by transfection with normal human DNA. **1986**, 83, 7034-8 | | 30 |
| 207 | Clastogen-induced chromosomal breakage as a marker for first trimester prenatal diagnosis of Fanconi anemia. *Human Genetics*, **1986**, 73, 86-8 | 6.3 | 52 |
| 206 | Comparison of the sensitivity of Fanconi anemia and normal fibroblasts to the induction of sister-chromatid exchanges by photoaddition of mono- and bi-functional psoralens. **1986**, 174, 241-6 | | 16 |
| 205 | The fate of 8-methoxypsoralen-photoinduced DNA interstrand crosslinks in Fanconi anemia cells of defined genetic complementation groups. **1987**, 184, 271-80 | | 36 |
| 204 | Studies of gene transfer and reversion to mitomycin C resistance in Fanconi anemia cells. **1987**, 184, 153-9 | | 10 |
| 203 | Genetic Diseases Associated with DNA and Chromosomal Instability. **1987**, 5, 85-108 | | 14 |
| 202 | New autosomal dominant radial ray hypoplasia syndrome. **1987**, 28, 647-54 | | 8 |
| 201 | Fanconi anemia, dyskeratosis congenita, and WT syndrome. **1987**, 3, 263-78 | | 4 |
| 200 | Fanconi anemia lymphocytes: effect of caffeine, adenosine and niacinamide during G2 prophase. **1988**, 199, 159-165 | | |
| 199 | Fanconi anemia--chromosome breakage studies in homozygotes and heterozygotes. **1988**, 33, 175-83 | | 25 |
| 198 | Lymphocyte subpopulations and lymphokine production in children with constitutional aplastic anemia. **1988**, 5, 143-51 | | 2 |
| 197 | The molecular genetics of the incision step in the DNA excision repair process. **1988**, 54, 309-65 | | 24 |
| 196 | Triphalangeal thumb. **1988**, 25, 505-20 | | 23 |
| 195 | A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. **1988**, 77, 773-5 | | 92 |
| 194 | Diseases with DNA damage-processing defects. **1988**, 295, 40-8 | | 43 |

| | | | |
|---|---|---|---|
| 193 | Chromosomal hypersensitivity in mutant MCN-151 mouse cells exposed to mitomycin C. **1989**, 225, 115-9 | | 5 |
| 192 | Late onset bone marrow failure associated with proximal fusion of radius and ulna: a new syndrome. **1989**, 71, 277-80 | | 13 |
| 191 | Myelodysplastic syndrome with trisomy 8 in an adolescent with Fanconi anaemia and selective IgA deficiency. **1989**, 31, 280-3 | | 19 |
| 190 | Dominantly transmitted hematologic dysfunction clinically similar to Fanconi anemia. **1989**, 32, 241-7 | | 2 |
| 189 | Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi anemia patients. **1989**, 217, 185-92 | | 42 |
| 188 | Cutaneous and extracutaneous neutrophilic infiltrates (Sweet syndrome) in three patients with Fanconi anemia. **1989**, 115, 726-9 | | 50 |
| 187 | Marrow hypoplasia associated with congenital neurologic anomalies in two siblings. **1990**, 79, 990-3 | | 1 |
| 186 | Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. **1990**, 8 Suppl 1, 76-89; discussion 89-91 | | 129 |
| 185 | Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents. *Human Genetics*, **1990**, 86, 151-61 | 6.3 | 7 |
| 184 | Fanconi anemia: evidence for linkage heterogeneity on chromosome 20q. **1991**, 9, 329-37 | | 46 |
| 183 | Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. **1991**, 51, 1-12 | | 226 |
| 182 | Defective DNA endonuclease activities in Fanconi anemia cells, complementation groups A and B. **1992**, 273, 57-71 | | 28 |
| 181 | Inherited defects in DNA repair and susceptibility to DNA-damaging agents. **1992**, 64-65 Spec No, 141-8 | | 7 |
| 180 | Cloning of cDNAs for Fanconi anaemia by functional complementation. **1992**, 356, 763-7 | | 527 |
| 179 | Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. **1992**, 1, 196-8 | | 270 |
| 178 | VACTERL with hydrocephalus: one end of the Fanconi anemia spectrum of anomalies?. **1992**, 43, 1032-4 | | 46 |
| 177 | Immunological probing of induction and repair of 8-methoxypsoralen photoadducts in DNA from Fanconi anemia and normal human fibroblasts: quantitative analysis by electron microscopy. **1993**, 18, 27-34 | | 6 |
| 176 | A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. **1993**, 4, 202-5 | | 141 |

| | | | |
|---|---|---|---|
| 175 | Fanconi anaemia and its variability. **1993**, 85, 9-14 | | 92 |
| 174 | Chromosomal breakage, endomitosis, endoreduplication, and hypersensitivity toward radiomimetric and alkylating agents: a possible new autosomal recessive mutation in a girl with craniosynostosis and microcephaly. *Human Genetics*, **1993**, 92, 339-46 | 6.3 | 11 |
| 173 | Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. **1993**, 294, 255-62 | | 47 |
| 172 | Fanconi anemia. **1994**, 330, 720-1 | | 1 |
| 171 | Fanconi anemia cells have a normal gene structure for topoisomerase I. *Human Genetics*, **1994**, 93, 583-66.3 | | 5 |
| 170 | The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population. **1994**, 3, 339-41 | | 35 |
| 169 | The Fanconi anemia polypeptide FACC is localized to the cytoplasm. **1994**, 91, 6712-6 | | 123 |
| 168 | Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. **1995**, 11, 341-3 | | 118 |
| 167 | Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. **1995**, 1, 1303-8 | | 65 |
| 166 | Fanconi Anemia. **1995**, 13, 41-49 | | 44 |
| 165 | Congenital and genetic disorders of hyperpigmentation. **1995**, 7, 148-196 | | 5 |
| 164 | Wiskott-Aldrich syndrome in a family with Fanconi anemia. **1996**, 129, 50-5 | | 8 |
| 163 | Correction of Fanconi Anemia Type C Phenotypic Abnormalities Using a Clinically Suitable Retroviral Vector Infection Protocol. **1996**, 5, 385-393 | | 10 |
| 162 | Bone marrow transplantation in Fanconi anemia. **1993**, 11 Suppl 2, 180-3 | | 11 |
| 161 | Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. **1996**, 12, 448-51 | | 221 |
| 160 | Multifocal osteosarcoma in a patient with Fanconi anemia. **1997**, 19, 251-3 | | 6 |
| 159 | Chromosome 7 and Haematological Malignancies. **1997**, 2, 359-72 | | |
| 158 | Bone marrow transplantation in patients with Fanconi anemia: experience with cyclophosphamide and total body irradiation conditioning regimen. **1997**, 14, 67-72 | | 1 |

| | | | |
|---|---|---|---|
| 157 | Molecular biology of Fanconi anemia. **1997**, 11, 1045-60 | | 20 |
| 156 | The Fanconi Anemia Polypeptide, FAC, Binds to the Cyclin-Dependent Kinase, cdc2. *Blood*, **1997**, 90, 1047-1054 | 2.1 | 89 |
| 155 | The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. **1997**, 17, 487-90 | | 179 |
| 154 | Fanconi anemia group A and D cell lines respond normally to inhibitors of cell cycle regulation. **1997**, 23, 371-7 | | 7 |
| 153 | Complementation group assignments in Fanconi anemia fibroblast cell lines from North America. **1997**, 23, 1-7 | | 15 |
| 152 | Monosomy 7 and 7q--associated with myeloid malignancy. **1997**, 11, 46-55 | | 51 |
| 151 | New molecular diagnostic tests for two congenital forms of anemia. **1997**, 11, 17-22 | | 8 |
| 150 | Omphalocele with absent radial ray (ORR): A case with diploid-triploid mixoploidy. **1998**, 75, 235-239 | | 8 |
| 149 | DNA Cross-Linker□Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287 | 2.2 | 59 |
| 148 | The Fanconi Anemia Proteins FAA and FAC Function in Different Cellular Compartments to Protect Against Cross-Linking Agent Cytotoxicity. *Blood*, **1998**, 92, 2229-2236 | 2.2 | 48 |
| 147 | Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase. *Blood*, **1998**, 92, 3050-3056 | 2.2 | 130 |
| 146 | Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C. *Blood*, **1999**, 93, 363-369 | 2.2 | 4 |
| 145 | Loss of FancC Function Results in Decreased Hematopoietic Stem Cell Repopulating Ability. *Blood*, **1999**, 94, 1-8 | 2.2 | 171 |
| 144 | A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. *Blood*, **1999**, 94, 3737-3747 | 2.2 | 119 |
| 143 | Expression of the Fanconi Anemia Group A Gene (Fanca) During Mouse Embryogenesis. *Blood*, **1999** , 94, 818-824 | 2.2 | 31 |
| 142 | In Vivo Selection of Wild-Type Hematopoietic Stem Cells in a Murine Model of Fanconi Anemia. *Blood*, **1999**, 94, 2151-2158 | 2.2 | 47 |
| 141 | Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). **1999**, 10, 2337-46 | | 106 |
| 140 | The diagnostic value of caf□au-lait macules. **1999**, 40, 877-90; quiz 891-2 | | 104 |

| | | | |
|---|---|---|---|
| 139 | Analysis of epitope-tagged forms of the dyskeratosis congenital protein (dyskerin): identification of a nuclear localization signal. **1999**, 25, 305-9 | | 15 |
| 138 | DNA repair and chromatin structure in genetic diseases. **1999**, 63, 257-310 | | 8 |
| 137 | Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. **2000**, 109, 121-9 | | 74 |
| 136 | The Inherited Bone Marrow Failure Syndromes: Fanconi Anemia, Dyskeratosis Congenita and Diamond-Blackfan Anemia. **2000**, 4, 183-215 | | 3 |
| 135 | Body proportions in Fanconi anemia heterozygotes. **2000**, 67, 797-801 | | |
| 134 | The Jak-Stat pathway in normal and perturbed hematopoiesis. *Blood*, **2000**, 95, 19-29 | 2.2 | 247 |
| 133 | Posttranscriptional cell cycle□dependent regulation of human FANCC expression. *Blood*, **2000**, 95, 3970-3977 | 2.2 | 18 |
| 132 | Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia. *Blood*, **2000**, 96, 859-863 | 2.2 | 30 |
| 131 | Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links. **2000**, 21, 741-51 | | 47 |
| 130 | Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?. **2000**, 3, 211-215 | | 9 |
| 129 | Aplasias medulares constitucionales. **2000**, 35, 1-9 | | |
| 128 | The genetics of Fanconi□ anaemia. **2000**, 13, 407-25 | | 24 |
| 127 | The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. **2001**, 74, 403-12 | | 61 |
| 126 | Positional cloning of a novel Fanconi anemia gene, FANCD2. **2001**, 7, 241-8 | | 335 |
| 125 | Correction of cross-linker sensitivity of Fanconi anemia group F cells by CD33-mediated protein transfer. *Blood*, **2001**, 98, 3817-22 | 2.2 | 1 |
| 124 | Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase. *Blood*, **2001**, 98, 1003-11 | 2.2 | 69 |
| 123 | Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. **2001**, 107, 744-54 | | 88 |
| 122 | Fanconi anemia proteins localize to chromatin and the nuclear matrix in a DNA damage- and cell cycle-regulated manner. **2001**, 276, 23391-6 | | 84 |

| | | | |
|---|---|---|---|
| 121 | Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. **2001**, 3, 14-23 | | 35 |
| 120 | Mitochondrial alterations in fanconi anemia fibroblasts following ultraviolet A or psoralen photoactivation. **2002**, 75, 159-66 | | 17 |
| 119 | Serum alpha-fetoprotein level in Fanconi anemia: evaluation of 33 Turkish patients. **2002**, 71, 275-8 | | 6 |
| 118 | Two different karyotypes with 1q abnormalities in a patient with Fanconi anemia. **2002**, 26, 1047-9 | | 4 |
| 117 | FANCL, as in ligase. **2003**, 35, 113-114 | | 7 |
| 116 | Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. **2003**, 286, 381-95 | | 17 |
| 115 | Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. **2003**, 17, 2021-35 | | 200 |
| 114 | Increased sensitivity of Fancc-deficient hematopoietic cells to nitric oxide and evidence that this species mediates growth inhibition by cytokines. *Blood*, **2003**, 101, 3877-84 | 2.2 | 15 |
| 113 | Phosphorylation of fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. **2004**, 279, 46035-45 | | 39 |
| 112 | FANCG is phosphorylated at serines 383 and 387 during mitosis. **2004**, 24, 8576-85 | | 36 |
| 111 | The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments. **2004**, 279, 26201-9 | | 39 |
| 110 | Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. **2004**, 11, 539-46 | | 28 |
| 109 | Spontaneous chromosome aberrations in Fanconi anemia patients are located at fragile sites and acute myeloid leukemia breakpoints. **1994**, 120, 47-50 | | 24 |
| 108 | Post-irradiation phosphorylation of structural maintenance chromosome 1 (SMC1) is independent of the Fanconi protein pathway. **2005**, 61, 1167-72 | | 8 |
| 107 | Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. **2005**, 130, 99-106 | | 33 |
| 106 | Flow cytometric characterization of the response of Fanconi anemia cells to mitomycin C treatment. **1982**, 2, 291-7 | | 72 |
| 105 | The Caenorhabditis elegans FancD2 ortholog is required for survival following DNA damage. **2005**, 141, 453-60 | | 15 |
| 104 | [Nosologic discussion between Fanconi disease and congenital dyskeratosis: 1 case of congenital bone marrow aplasia]. **2006**, 13, 1239-43 | | 0 |

| | | | |
|---|---|---|---|
| 103 | Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells. *Blood*, **2006**, 107, 2605-12 | 2.2 | 33 |
| 102 | Aplasies m□ullaires constitutionnelles. **2006**, 1, 1-10 | | |
| 101 | Guido Fanconi (1892-1979): a jack of all trades. **2006**, 6, 893-8 | | 57 |
| 100 | Fanconi anaemia genes and susceptibility to cancer. **2006**, 25, 5875-84 | | 157 |
| 99 | Endocrine abnormalities in patients with Fanconi anemia. **2007**, 92, 2624-31 | | 106 |
| 98 | Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. **2007**, 129, 289-301 | | 543 |
| 97 | Immunodeficiency, radiosensitivity, and the XCIND syndrome. **2007**, 38, 87-101 | | 19 |
| 96 | Radial ray defects and associated anomalies. **1989**, 35, 322-30 | | 34 |
| 95 | Association of aplastic anaemia and Fanconi□ disease with HLA-DRB1 alleles. **2008**, 35, 453-6 | | 16 |
| 94 | What□ in a cancer syndrome? Genes, phenotype and pathology. **2008**, 40, 247-59 | | 1 |
| 93 | A Case of Fanconi Anemia Diagnosed by a Chromosome Breakage Test with Skin Fibroblasts. **2008**, 43, 62 | | 1 |
| 92 | Validation of Fanconi anemia complementation Group A assignment using molecular analysis. **2009**, 11, 183-92 | | 11 |
| 91 | Iron kinetics and erythropoiesis in Fanconi□ anaemia. **1978**, 21, 29-39 | | 7 |
| 90 | Dyskeratosis congenita. Haematologic, cytogenetic, and dermatologic studies. **1984**, 32, 461-8 | | 20 |
| 89 | Fanconi anemia in infancy: report of hematopoietic stem cell transplantation to a 13-month-old patient. **2009**, 89, 722-3 | | 3 |
| 88 | Haematopoeitic cell transplantation for Fanconi anaemia - when and how?. **2010**, 149, 14-21 | | 97 |
| 87 | Normal red blood cells partially decrease diepoxybutane-induced chromosome breakage in cultured lymphocytes from Fanconi anaemia patients. **2010**, 43, 573-8 | | 1 |
| 86 | A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. **2010**, 39, 36-47 | | 261 |

| | | | |
|---|---|---|---|
| 85 | Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. **2010**, 39, 25-35 | | 226 |
| 84 | Discovering moderate-risk breast cancer susceptibility genes. **2010**, 20, 268-76 | | 75 |
| 83 | DNA interstrand crosslink repair and cancer. **2011**, 11, 467-80 | | 691 |
| 82 | FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer. **2011**, 130, 1043-9 | | 15 |
| 81 | Anatomic and etiological classification of congenital limb deficiencies. **2011**, 155A, 1225-35 | | 59 |
| 80 | [Fanconi anemia in 2012: diagnosis, pediatric follow-up and treatment]. **2012**, 19, 1100-9 | | 0 |
| 79 | Fanconi Anemia. **2012**, 795-803 | | |
| 78 | Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. **2012**, 95, 675-9 | | 22 |
| 77 | Other Hereditary Red Blood Cell Disorders. **2013**, 1-25 | | 0 |
| 76 | 50 Years of Seminars in Hematology. *Seminars in Hematology*, **2013**, 50, 1-3 | 4 | 1 |
| 75 | Genetic predispositions to childhood leukemia. **2013**, 4, 270-90 | | 51 |
| 74 | Aplastic Anemia. **2014**, 1446-1461 | | 1 |
| 73 | Additional Diseases Associated with Defective Responses to DNA Damage. **2014**, 979-999 | | |
| 72 | Radial Deficiency. **2014**, 1-30 | | 0 |
| 71 | Global and disease-associated genetic variation in the human Fanconi anemia gene family. **2014**, 23, 6815-25 | | 9 |
| 70 | HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. **2014**, 20, 571-6 | | 42 |
| 69 | Physical interaction between SLX4 (FANCP) and XPF (FANCQ) proteins and biological consequences of interaction-defective missense mutations. **2015**, 35, 48-54 | | 11 |
| 68 | Alternative donor hematopoietic cell transplantation for Fanconi anemia. *Blood*, **2015**, 125, 3798-804 | 2.2 | 67 |

| | | |
|---|---|---|
| 67 | FANCD2 influences replication fork processes and genome stability in response to clustered DSBs. **2015**, 14, 1809-22 | 19 |
| 66 | Radial Deficiency. **2015**, 237-263 | |
| 65 | Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. **2016**, 53, 672-680 | 58 |
| 64 | Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex. **2016**, 6, 24712 | 19 |
| 63 | Hematopoietic Cell Transplantation for Fanconi Anemia. **2016**, 923-946 | 1 |
| 62 | Fan1 deficiency results in DNA interstrand cross-link repair defects, enhanced tissue karyomegaly, and organ dysfunction. **2016**, 30, 645-59 | 33 |
| 61 | DNA replication stress: from molecular mechanisms to human disease. **2017**, 126, 1-15 | 47 |
| 60 | Peripheral blood cytogenetic methods. **2017**, 87-117 | 1 |
| 59 | Regulation of Hematopoiesis and Hematological Disease by TGF-Family Signaling Molecules. **2017**, 9, | 19 |
| 58 | Fanconi Anemia. **2017**, 1031-1044 | |
| 57 | Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks. **2018**, 64, 1-9 | 12 |
| 56 | FANCD2 Promotes Meiotic Crossover Formation. **2018**, 30, 415-428 | 24 |
| 55 | Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy. **2018**, 10, | 32 |
| 54 | Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. **2019**, 115, 297-324 | 12 |
| 53 | Cord blood transplantation for bone marrow failure syndromes: state of art. **2019**, 6, 39 | 6 |
| 52 | Compromised repair of radiation-induced DNA double-strand breaks in Fanconi anemia fibroblasts in G2. **2020**, 96, 102992 | 4 |
| 51 | Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). **2020**, 55, 1485-1490 | 1 |
| 50 | Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT. **2021**, 96, 571-579 | 3 |

| | | | |
|---|---|---|---|
| 49 | Disabling the Fanconi Anemia Pathway in Stem Cells Leads to Radioresistance and Genomic Instability. **2021**, 81, 3706-3716 | | |
| 48 | Feasibility of breast radiation therapy in a Fanconi Anemia patient diagnosed with breast cancer: A case report and review of literature. **2021**, 28, 129-132 | | |
| 47 | Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. **2021**, 96, 1450-1460 | | 1 |
| 46 | Three Cases of Esophageal Cancer Related to Fanconi Anemia. *Internal Medicine*, **2021**, 60, 2953-2959 | 1.1 | 1 |
| 45 | DNA Repair Enzymes in Mammalian Cells. **1977**, 263-322 | | 24 |
| 44 | Chromosome-breakage syndromes: different genes, different treatments, different cancers. *Basic Life Sciences*, **1980**, 15, 429-39 | | 13 |
| 43 | Hereditary Disorders of Platelet Function. *Blood Cell Biochemistry*, **1991**, 77-112 | | 2 |
| 42 | Chromosome instability syndromes: lessons for carcinogenesis. *Current Topics in Microbiology and Immunology*, **1997**, 221, 71-148 | 3.3 | 53 |
| 41 | International Fanconi Anemia Registry: First Report. **1989**, 3-17 | | 8 |
| 40 | Complementation Studies in Fanconi Anemia. **1989**, 213-225 | | 2 |
| 39 | Complementation and Gene Transfer Studies in Fanconi Anemia. **1989**, 226-235 | | 9 |
| 38 | Clinical Aspects of a Cluster of 42 Patients in South Africa with Fanconi Anemia. **1989**, 34-46 | | 3 |
| 37 | Bone Marrow Transplantation for Fanconi Anemia. **1989**, 60-68 | | 12 |
| 36 | Chromosomal Breakage in Response to Cross-linking Agents in the Diagnosis of Fanconi Anemia. **1989**, 83-92 | | 7 |
| 35 | Management of Congenital Hand Anomalies. **2011**, 1631-1646.e4 | | 4 |
| 34 | Cytoplasmic localization of FAC is essential for the correction of a prerepair defect in Fanconi anemia group C cells. *Journal of Clinical Investigation*, **1996**, 97, 2003-10 | 15.9 | 54 |
| 33 | MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. *Journal of Clinical Investigation*, **1997**, 100, 2873-80 | 15.9 | 43 |
| 32 | The Fanconi Anemia Polypeptide, FAC, Binds to the Cyclin-Dependent Kinase, cdc2. *Blood*, **1997**, 90, 1043-1054 | 2.1 | 42 |

| | | | |
|---|---|---|---|
| 31 | DNA Cross-Linker Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287 | 2.2 | 1 |
| 30 | Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase. *Blood*, **1998**, 92, 3050-3056 | 2.2 | 8 |
| 29 | A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. *Blood*, **1999**, 94, 3737-3747 | 2.2 | 8 |
| 28 | The Jak-Stat pathway in normal and perturbed hematopoiesis. *Blood*, **2000**, 95, 19-29 | 2.2 | 63 |
| 27 | Posttranscriptional cell cycle dependent regulation of human FANCC expression. *Blood*, **2000**, 95, 3970-3977 | 2.2 | 9 |
| 26 | Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia. *Blood*, **2000**, 96, 859-863 | 2.2 | 6 |
| 25 | The concept and practice of Fanconi Anemia: from the clinical bedside to the laboratory bench. *Translational Pediatrics*, **2013**, 2, 112-9 | 4.2 | 5 |
| 24 | Fanconi anemia pathway defects in inherited and sporadic cancers. *Translational Pediatrics*, **2014**, 3, 300-4 | 4.2 | 11 |
| 23 | Sources Used in Preparation of Commentaries. **2000**, 1059-1060 | | |
| 22 | Cytogenetics of Fanconi Anaemia and Related Chromosome Disorders. *Novartis Foundation Symposium*, 261-306 | | 1 |
| 21 | Chromosomal and Other Genetic Influences on Birth Weight Variation. *Novartis Foundation Symposium*, 127-164 | | 5 |
| 20 | Fanconi Anaemia. *Novartis Foundation Symposium*, 103-114 | | |
| 19 | Interrelationship of the Fanconi Anemia/BRCA Pathway. **2009**, 65-80 | | |
| 18 | Cell and Molecular Aging. **2011**, 5-37 | | |
| 17 | Phenotypic and Genetic Heterogeneity in Fanconi Anemia, Fate of Cross-Links, and Correction of the Defect by DNA Transfection. **1989**, 196-210 | | 2 |
| 16 | Successful Treatment of Acquired Amegakaryocytic Thrombocytopenic Purpura with Cyclophosphamide. *Annals of Saudi Medicine*, **1990**, 10, 344-345 | 1.6 | |
| 15 | Molecular Mechanisms Responsible for Repair of Adducts Induced in Human Cellular DNA by Puva. **1994**, 497-533 | | |
| 14 | Medical Background: Human DNA Damage Recognition and Processing Disorders. *Molecular Biology Intelligence Unit*, **1997**, 1-30 | | |

| | | | |
|---|---|---|---|
| 13 | The Fanconi Anemia Proteins FAA and FAC Function in Different Cellular Compartments to Protect Against Cross-Linking Agent Cytotoxicity. *Blood*, **1998**, 92, 2229-2236 | 2.2 | 3 |
| 12 | Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C. *Blood*, **1999**, 93, 363-369 | 2.2 | |
| 11 | Expression of the Fanconi Anemia Group A Gene (Fanca) During Mouse Embryogenesis. *Blood*, **1999** , 94, 818-824 | 2.2 | |
| 10 | In Vivo Selection of Wild-Type Hematopoietic Stem Cells in a Murine Model of Fanconi Anemia. *Blood*, **1999**, 94, 2151-2158 | 2.2 | 1 |
| 9 | Fanconi Anemia. **2016**, 1-14 | | |
| 8 | Inherited Bone Marrow Failure Syndrome, TAM. **2017**, 145-170 | | |
| 7 | The Fanconi Anemia/BRCA Pathway. **2006**, 67-81 | | |
| 6 | Fanconi Anemia. **2006**, 389-394 | | |
| 5 | Congenital malformations and developmental disabilities in ataxia-telangiectasia, Fanconi anemia, and xeroderma pigmentosum families. *American Journal of Human Genetics*, **1982**, 34, 781-93 | 11 | 21 |
| 4 | The identification of fanconi anemia genotypes by clastogenic stress. *American Journal of Human Genetics*, **1982**, 34, 794-810 | 11 | 41 |
| 3 | Segregation analysis with uncertain ascertainment: application to Fanconi anemia. *American Journal of Human Genetics*, **1988**, 42, 889-97 | 11 | 14 |
| 2 | Two complementation groups of Fanconi anemia differ in their phenotypic response to a DNA-crosslinking treatment. *Human Genetics*, **1987**, 75, 45-7 | 6.3 | 54 |
| 1 | Genetic heterogeneity of Fanconi anemia demonstrated by somatic cell hybrids. *Human Genetics*, **1980**, 56, 81-4 | 6.3 | 44 |